Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

This article was reviewed by Knox Beasley. Key Takeaways: 1mg oral finasteride effectively treats hair loss and is the ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

The research lays a foundation for the possibility that aggressive prostate cancer can probably be detected through a few drops of semen or blood in the long term. Prostate cancer is the most common ...

Overview of Ac‑225 PSMA therapy, what real patient cases can illustrate about the treatment pathway, and key steps for eligibility review and choosing a center.

The therapy shrunk tumors in 46 percent of patients in a Phase I trial and showed strong PSA responses at the recommended dose.

Eighty-five original research projects from aspiring physician-scientists were on display at the 2026 Medical Student Research Forum at the Jacobs School of Medicine and Biomedical Sciences.

Bayer presents positive results from global phase I first-in-human, dose-escalation PAnTHa study at ASCO GU 2026: Berlin, Germany Monday, March 2, 2026, 13:00 Hrs [IST] Bayer anno ...

Germany’s Bayer has announced encouraging results from the ongoing global Phase I first-in-human dose-escalation PAnTHa study of 225Ac-PSMA-Trillium, a targeted alpha therapy in advanced metastatic ca ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

BALTIMORE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Early ...